Could a single dose shield preemie lungs?
NCT ID NCT05898633
First seen Apr 14, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This early-stage trial tested a new drug called rfhSP-D in 18 very premature babies (born before 30 weeks) to find the safest dose. The goal is to see if this drug can prevent chronic lung disease, a common complication in preemies. The study focused on safety and dosing, not yet on effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHOPULMONARY DYSPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University College London Hospitals
London, United Kingdom
Conditions
Explore the condition pages connected to this study.